David Mcintosh

David M. McIntosh is head of Ropes & Gray’s intellectual property transactions practice group. He advises a wide range of companies, investors, and institutions primarily in the life sciences industry in all manner of transactions involving intellectual property, including technology licensing, strategic collaborations, mergers and acquisitions, joint ventures,  supply and distribution arrangements, co-promotion agreements, outsourcing transactions, and other strategic commercial agreements.

David’s practice focuses on the life sciences industry, but he also has had extensive experience advising companies and investors in the technology and branded product industries with respect to strategic transactions involving intellectual property as well as day-to-day commercial and corporate matters.

David also provides guidance on integrating advice from other legal experts, such as patent specialists, litigators and regulatory advisors, so that it aligns with companies’ corporate strategy and practices.

EDUCATION :

• BA, Duke University, 1993
• JD, summa cum laude, Boston College Law School, 1997; Executive Editor, Boston College Law Review

ADMISSIONS : Massachusetts, 1998

MEMBERSHIP & AFFILIATIONS :

• Boston Bar Association
• Massachusetts Bar Association
• American Intellectual Property Law Association
• Licensing Executive Society

PROFESSIONAL & CIVIC ACTIVITIES :

• Former co-chair of the Boston Bar Association’s Intellectual Property Section and Intellectual Property Law Committee; current at-large member of BBA’s IP Section
• Speaker, intellectual property, licensing, and privacy matters including presentations for the Boston Bar Association, Massachusetts Continuing Legal Education, Inc., the Boston Patent Law Association, the Massachusetts Software Council, the American Conference Institute, Global IP Exchange, and the Global Strategic Management Institute

Experience :

• Represented biopharmaceutical company Sarepta Therapeutics in a strategic investment and licensing transaction with Lacerta Therapeutics, a gene therapy company, in which Sarepta entered into a license and option agreement for up to three new CNS-targeted gene therapy programs, including exclusive rights to Lacerta’s gene therapy candidate for Pompe Disease and options to two additional candidates, and made an equity investment of $30 million in Lacerta.
• Represented Takeda Pharmaceutical Company Limitedin a partnership with Ambys Medicines, a company launched by Takeda and Third Rock Ventures, to discover and develop novel cell and gene therapies for liver disease. Takeda has committed $100 million and retains options to develop and commercialize products in certain geographies, including participation in the Series A financing.
• Advised Blueprint Medicines Corporation in connection with an exclusive collaboration and license agreement with CStone Pharmaceuticals, a China-based clinical stage biopharmaceutical company, concerning the development and commercialization of three investigational cancer therapies in mainland China, Hong Kong, Macau and Taiwan. At the time of its completion, this transaction was the largest investigational cancer therapeutic licensing deal ever done in China.
• Advised Shire Plc in a collaboration with Rani Therapeutics to exclusively conduct research on the use of Rani’s Pill(TM) technology for the oral delivery of factor VIII (FVIII) therapy for patents with hemophilia A. As part of the collaboration agreement, Shire was allowed an exclusive licensing option to develop and commercialize the Pill(TM) technology following the completion of feasibility studies.
• Represented Homology Medicines in its research and development collaboration with Novartis to use Homology’s gene editing technology to develop new treatments for select ophthalmic targets and hemoglobin blood disease.
• Represented Akebia Therapeutics, Inc. in an exclusive licensing agreement with Janssen Pharmaceutical under which Akebia in-licensed a portfolio of well-characterized HIF pathway compounds with potential applications across multiple therapeutics areas.
• Represented Takeda Pharmaceuticals in connection with the spin-out of Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders.
• Represented Genzyme Corporation in connection with the acquisition of Caprelsa®, a rare disease therapy to treat symptomatic or progressive medullary thyroid carcinoma, from AstraZeneca.
• Represented Becton Dickinson in connection with various acquisitions, dispositions and license and development transactions.
• Represented Synageva BioPharma in connection with various licensing transactions, including transactions with Shire and the University of Georgia.